Therapy resistant urticaria as a long-term symptom of an incomplete Schnitzler syndrome.

Anakinra Canakinumab Chronic urticaria Gammopathy Schnitzler syndrome

Journal

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology
ISSN: 1710-1484
Titre abrégé: Allergy Asthma Clin Immunol
Pays: England
ID NLM: 101244313

Informations de publication

Date de publication:
26 Jul 2023
Historique:
received: 23 08 2022
accepted: 03 07 2023
medline: 27 7 2023
pubmed: 27 7 2023
entrez: 26 7 2023
Statut: epublish

Résumé

Recurring therapy resistant hives, accompanied by IgM-gammopathy, fever and joint pain can indicate Schnitzler syndrome, a rare autoimmune disorder. There is currently no approved treatment, but complete remission of symptoms can be induced with IL-1 antagonists. A patient with a history of chronic urticaria presented frequently at the outpatient clinic with severe hives and was treated unsuccessfully with antihistamines and omalizumab. After several years, additional symptoms such as joint pain, recurrent fever, and IgM-gammopathy developed. After the diagnostic criteria for Schnitzler syndrome were met, treatment with anakinra was initiated and resulted in an improvement of the symptoms. Shortly after the first injection, the patient developed large and painful erythematous lesions at the injection sites, leading to discontinuation of treatment and a rapid recurrence of symptoms. Subsequently, treatment with a longer-acting IL-1 antagonist (canakinumab) was initiated, resulting in a complete remission of symptoms. This case report demonstrates that patients with urticarial symptoms that are not relieved by typical treatments should prompt repeated reassessments of the diagnosis, even years later, because gammopathy and other diagnostic criteria for Schnitzler syndrome can occur with a delay.

Sections du résumé

BACKGROUND BACKGROUND
Recurring therapy resistant hives, accompanied by IgM-gammopathy, fever and joint pain can indicate Schnitzler syndrome, a rare autoimmune disorder. There is currently no approved treatment, but complete remission of symptoms can be induced with IL-1 antagonists.
CASE PRESENTATION METHODS
A patient with a history of chronic urticaria presented frequently at the outpatient clinic with severe hives and was treated unsuccessfully with antihistamines and omalizumab. After several years, additional symptoms such as joint pain, recurrent fever, and IgM-gammopathy developed. After the diagnostic criteria for Schnitzler syndrome were met, treatment with anakinra was initiated and resulted in an improvement of the symptoms. Shortly after the first injection, the patient developed large and painful erythematous lesions at the injection sites, leading to discontinuation of treatment and a rapid recurrence of symptoms. Subsequently, treatment with a longer-acting IL-1 antagonist (canakinumab) was initiated, resulting in a complete remission of symptoms.
CONCLUSION CONCLUSIONS
This case report demonstrates that patients with urticarial symptoms that are not relieved by typical treatments should prompt repeated reassessments of the diagnosis, even years later, because gammopathy and other diagnostic criteria for Schnitzler syndrome can occur with a delay.

Identifiants

pubmed: 37496089
doi: 10.1186/s13223-023-00819-x
pii: 10.1186/s13223-023-00819-x
pmc: PMC10373319
doi:

Types de publication

Journal Article

Langues

eng

Pagination

64

Informations de copyright

© 2023. The Author(s).

Références

BMC Musculoskelet Disord. 2021 Mar 8;22(1):257
pubmed: 33685423
J Allergy Clin Immunol. 2011 Dec;128(6):1352-4
pubmed: 21704363
Orphanet J Rare Dis. 2010 Dec 08;5:38
pubmed: 21143856
Arthritis Res Ther. 2015 Jul 22;17:187
pubmed: 26198339
Leuk Lymphoma. 2002 Jan;43(1):181-6
pubmed: 11908725
Scand J Rheumatol. 2015;44(6):521-2
pubmed: 26395927
Br J Dermatol. 2008 Jan;158(1):182-4
pubmed: 17941941
Semin Arthritis Rheum. 2007 Dec;37(3):137-48
pubmed: 17586002
Br J Dermatol. 2014 Sep;171(3):505-11
pubmed: 24665899
J Allergy Clin Immunol. 2016 Oct;138(4):1161-1169.e6
pubmed: 27040374
Allergy. 2012 Jul;67(7):943-50
pubmed: 22583335
Allergy. 2013;68(5):562-8
pubmed: 23480774
Semin Arthritis Rheum. 2013 Feb;42(4):413-6
pubmed: 22901459

Auteurs

Viktoria Puxkandl (V)

Department of Dermatology, Comprehensive Allergy Center, Kepler University Hospital Linz & Johannes Kepler University, Krankenhausstrasse 9, 4020, Linz, Austria.

Antonia Currie (A)

Department of Dermatology, Comprehensive Allergy Center, Kepler University Hospital Linz & Johannes Kepler University, Krankenhausstrasse 9, 4020, Linz, Austria.

Wolfram Hoetzenecker (W)

Department of Dermatology, Comprehensive Allergy Center, Kepler University Hospital Linz & Johannes Kepler University, Krankenhausstrasse 9, 4020, Linz, Austria. wolfram.hoetzenecker@kepleruniklinikum.at.

Sabine Altrichter (S)

Department of Dermatology, Comprehensive Allergy Center, Kepler University Hospital Linz & Johannes Kepler University, Krankenhausstrasse 9, 4020, Linz, Austria.
Departement of Dermatology and Allergology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.

Classifications MeSH